September 3rd, 2014
FAME 2 at 2 Years: Better with Time?
CardioExchange Editors, Staff
The CardioExchange editors ask whether the 2-year findings from FAME 2 are more compelling than the 7-month findings.
September 4th, 2012
ESC Trials: The Best And The Worst
Larry Husten, PHD
Larry Husten is back from ESC and discussing two trials that exemplify how medicine is supposed to work, and one that exemplifies what can go wrong, especially when commercial interests are at stake.
NEJM Journal Watch — Recent Cardiology Articles- Sex-Based Disparity in CABG Outcomes: Are We Moving Toward Parity?
- Can Genetic and Social Risk Scores Improve Cardiac Risk Prediction?
- Extensive Ablation vs. Pulmonary Vein Isolation in Persistent Atrial Fibrillation
- Can a Novel Stent Design Improve Long-Term Outcomes of Percutaneous Coronary Intervention?
- Are Angiographically-Derived Coronary Physiology Measurements Ready for Use in the Cath Lab?